Kringle Pharma Gestione

Gestione criteri di controllo 1/4

Kringle Pharma Il CEO è Kiichi Adachi, nominato in Dec2016, ha un mandato di 7.92 anni. possiede direttamente 1.12% delle azioni della società, per un valore di ¥ 64.14M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.9 anni e 5.9 anni.

Informazioni chiave

Kiichi Adachi

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.9yrs
Proprietà del CEO	1.1%
Durata media del management	1.9yrs
Durata media del Consiglio di amministrazione	5.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Jun 15

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Mar 02

AMMINISTRATORE DELEGATO

Kiichi Adachi (57 yo)

7.9yrs

Mandato

Kiichi Adachi, Ph D., has been President at Kringle Pharma, Inc since December 27, 2016. Kiichi Adachi serves as a Director of Kringle Pharma, Inc. since December 2005.Kiichi Adachi was Research Scientist...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kiichi Adachi	President & Director	7.9yrs	Nessun dato	1.12% ¥ 64.1m
Tomoya Shimojo	Chief Financial Officer & Director of Accounting and Corporate Planning	no data	Nessun dato	Nessun dato
Kunio Matsumoto	Chief Scientific Officer	no data	Nessun dato	Nessun dato
Koichi Murakami	GM of Corporate Planning Management Department & Director	no data	Nessun dato	Nessun dato
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.9yrs	Nessun dato	Nessun dato
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	Nessun dato	Nessun dato

1.9yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di 4884 non è considerato esperto (durata media 1.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Kiichi Adachi	President & Director	18.9yrs	Nessun dato	1.12% ¥ 64.1m
Koichi Murakami	GM of Corporate Planning Management Department & Director	2.9yrs	Nessun dato	Nessun dato
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.9yrs	Nessun dato	Nessun dato
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	Nessun dato	Nessun dato
Kohichiro Yoshino	Independent Outside Director	5.9yrs	Nessun dato	Nessun dato
Akihiro Tomoyasu	Part Time Director	7.9yrs	Nessun dato	Nessun dato
Kazuto Ninomiya	Audit & Supervisory Board Member	5.9yrs	Nessun dato	Nessun dato
Masahiro Motokawa	Audit & Supervisory Board Member	5.9yrs	Nessun dato	Nessun dato
Yosuke Yamaguchi	Audit & Supervisory Board Member	5.9yrs	Nessun dato	Nessun dato
Masato Fukui	Independent Outside Director	3.9yrs	Nessun dato	Nessun dato

5.9yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4884 sono considerati esperti (durata media dell'incarico 5.9 anni).

Kringle Pharma Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

No independent directors

Recent updates

Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024

Kringle Pharma, Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023)

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023)

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024

Kringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024

Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022)

First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022)

Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar

Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023

Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023

Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

Kringle Pharma, Inc. Submits Clinical Trial Application

Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University

Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022

Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021)

Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALS

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021)

Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

No independent directors

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022

Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of Als

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021

Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021

Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021

Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media